Abbott Laboratories settled litigation related to its specialty preterm infant formulas for approximately $670 million, addressing claims from a key case and over 2,000 additional infants. This resolution aims to lessen the company's long-term litigation risks and ongoing financial liabilities.
Key Highlights
- Abbott Laboratories entered agreements totaling approximately $670 million to settle the Gill case and claims for around 2,000 additional infants.
- The previous Jury verdict in the Gill case resulted in damages of $495 million, which Abbott appealed but ultimately decided to resolve.
- Abbott Laboratories (NYSE: ABT) has reached significant agreements to settle ongoing litigation concerning its specialty formulas designed for preterm infants, totaling approximately $670 million.
Abbott Laboratories (NYSE: ABT) has reached significant agreements to settle ongoing litigation concerning its specialty formulas designed for preterm infants, totaling approximately $670 million. This settlement addresses claims related to the high-profile Gill case, where a jury awarded $495 million in damages, and involves roughly 2,000 infants. By opting to settle rather than continuing its appeal, the company aims to reduce its financial exposure and simplify ongoing litigation concerning its products.
Settlement Details
The settlement comprises resolutions to both the Gill lawsuit and associated claims from additional plaintiffs. Abbott previously faced a substantial judgment of approximately $600 million, including accrued interest, from the Gill decision, which the company had appealed. The agreements signal Abbott’s strategic choice to clear a major hurdle in its legal battles rather than prolonging litigation.
While Abbott emphasizes its confidence in the safety of its infant formulas, the decision to settle is framed as a constructive step toward resolving a web of pending claims.
Legal Environment
These cases are complex, as they involve claims naming both Abbott and other manufacturers without clear distinctions on which formula was consumed. Abbott continues to assess its legal claims, focusing on identifying and potentially eliminating disputes that lack substantial basis. The ongoing litigation environment is complex, with Abbott contending with claims that range in merit and connection to its products.
Safety Assurance
Despite the ongoing legal challenges, Abbott Laboratories maintains that its formulas are safe and recognize the necessity of these products in clinical settings for vulnerable infants. The FDA, CDC, and various medical organizations, including the American Academy of Pediatrics, acknowledge that, while breast milk is optimal, preterm infant formula is essential when breast milk is unavailable. Abbott’s commitment to the safety and importance of its specialty formula remains firm, underlined by support from leading medical authorities.
Future Considerations
Looking forward, the outcome of the remaining lawsuits will be key for Abbott Laboratories. The company continues to work on identifying claims that may lack factual support or have overlapping allegations against other entities. The focus on resolving these disputes promptly is important for Abbott as it navigates the complexities of ongoing legal scrutiny.
Observers will be particularly attentive to Abbott's next steps in managing the remaining litigation and any developments that might arise in its defense strategies.
Peers Moving on This News
- Intuitive Surgical Inc (NASDAQ: ISRG) up 0.7%
- Stryker Corp (NYSE: SYK) little changed
- Boston Scientific Corporation (NYSE: BSX) up 0.6%






Please wait processing your request...